key: cord-0918459-o8btlpku authors: Nguyen, Betty; Tosti, Antonella title: Alopecia in COVID-19 Patients: Systematic Review and Meta-analysis date: 2022-02-22 journal: JAAD Int DOI: 10.1016/j.jdin.2022.02.006 sha: 78d19086bd4e514e46dc4b61b9eddf4e081551d3 doc_id: 918459 cord_uid: o8btlpku Background COVID-19 infection is associated with androgenetic alopecia, telogen effluvium, and alopecia areata. No studies have analyzed the aggregate data to date. Objective We conducted a systematic review to characterize the types, incidence, timing, and clinical outcomes of COVID-19-associated alopecia. Methods We searched PubMed/MEDLINE, Scopus, and Embase for articles published between November 2019 and August 2021 using keywords “alopecia” or “hair” and COVID-19 search terms, identifying 41 original articles describing alopecia patients with COVID-19. Results This review includes 1,826 alopecia patients with COVID-19 (mean age 54.5 years, 54.3% male). The most common types of alopecia identified were androgenetic alopecia (30.7%, 86.4% male), telogen effluvium (19.8%, 19.3% male), and alopecia areata (7.8%, 40.0% male). Androgenetic alopecia preceded COVID-19 symptoms. Telogen effluvium was usually newly triggered by COVID-19 (93.6%). Alopecia areata usually occurred in patients with pre-existing disease (95.1%). Limitations Definitions of COVID-19 onset varied. Studies differed in methodology and were susceptible to reporting and sampling bias. Studies with large sample sizes might exert disproportionate influence on data. Conclusion Androgenetic alopecia may be a risk factor for severe COVID-19 infection, while telogen effluvium presents as a sequela of COVID-19 infection. Alopecia areata generally occurs as a relapse in patients with pre-existing alopecia. • Telogen effluvium and alopecia areata are COVID-19 infection sequelae. Androgenetic 59 alopecia may increase the risk for severe infection. 60 • Alopecia areata usually occurs as a relapse in patients with pre-existing disease. Telogen 61 effluvium is newly triggered by COVID-19 and is self-resolving. COVID-19 patients with 62 androgenetic alopecia may benefit from anti-androgen therapy. Given the growing number of reports documenting associations between COVID-19 and 75 certain types of alopecia, we sought to summarize these findings in a systematic review and meta-76 analysis. Recently published review articles have summarized findings from reports documenting 77 associations between COVID-19 and AGA, but no reviews have pooled data from all types of 78 COVID-19-associated alopecia. 4-6 To our knowledge, this paper is the first comprehensive review 79 to include all published studies describing hair-related manifestations of COVID-19. In this report, 80 we summarize the demographic information of affected patients and the types, incidence, timing, 81 and clinical outcomes of types of alopecia associated with COVID-19. infection. An increased prevalence of AGA in patients with severe COVID-19 has been reported 154 by 5 of 6 studies. 14, 16, 33, 42, 45 A report found that 71% of patients (n = 41) hospitalized with COVID- on patients hospitalized with severe COVID-19 in Iran also found a comparable 73.7% prevalence 160 of AGA in men and 56.1% in women; interestingly, the authors of this study found no association 161 between AGA and COVID-19 severity, 42 whereas 3 separate reports found that AGA was 162 associated with increased COVID-19 severity. 16, 33, 45 After pooling data from these reports, we The mechanism of this association is thought to be related to androgen-mediated 171 upregulation of the transmembrane serine protease 2 (TMPRSS2), facilitating entry of SARS- CoV-2 into cells through the angiotensin-converting enzyme (ACE) 2 receptor. 52,53 We identified 173 2 studies that reported androgen-deprivation therapies (ADT) could be protective against COVID-174 19. One prospective cohort study of 77 males hospitalized with COVID-19 found that patients who 175 had taken ADT for at least 6 months prior to hospitalization were less likely to be admitted to the 176 intensive care unit (n=1/12, 8%) compared to those who had not taken ADT (n=38/65, 58%) (p = The mechanism of the association between COVID-19 and TE is thought to be related to 197 upregulation of pro-inflammatory cytokines, including IL-1b, IL-6, tumor necrosis factor (TNF)-198 α, and interferon (IFN)-γ, that may induce catagen development and subsequent TE. 11,60-63 While 199 the large sex bias for TE seen in our review (80.7% female) may be due to sex differences in • Telogen effluvium and alopecia areata are COVID-19 infection sequelae. Androgenetic alopecia may increase the risk for severe infection. • Alopecia areata usually occurs as a relapse in patients with pre-existing disease. Telogen effluvium is newly triggered by COVID-19 and is self-resolving. COVID-19 patients with androgenetic alopecia may benefit from anti-androgen therapy. COVID-19 and dermatology: a 250 comprehensive guide for dermatologists Cutaneous signs in 253 COVID-19 patients: A review Cutaneous manifestations and 255 considerations in COVID-19 pandemic: A systematic review Androgenetic alopecia and 258 COVID-19: A review of the hypothetical role of androgens Sex differences in COVID-19: the role of 261 androgens in disease severity and progression The role of androgens in COVID-19 Time of onset and duration of post-COVID-265 19 acute telogen effluvium Rapidly progressive alopecia areata totalis in a COVID-19 patient, 268 unresponsive to tofacitinib Alopecia areata in a COVID-19 patient: A 270 case report Clinical characteristics and outcomes of 272 adult patients admitted with COVID-19 in East London: a retrospective cohort analysis Pathobiology questions raised by 275 telogen effluvium and trichodynia in COVID-19 patients COVID-19: association with rapidly progressive forms of alopecia areata. Int 278 A preliminary observation: Male pattern 282 hair loss among hospitalized COVID-19 patients in Spain -A potential clue to the role of 283 androgens in COVID-19 severity Different hair loss patterns in two pediatric 285 patients with COVID-19-associated multisystem inflammatory syndrome in children Male balding is a major risk factor for severe 288 COVID-19 A Case of Acute Telogen Effluvium After SARS-CoV-2 290 Infection Acral rash in a child with COVID-19 Telogen effluvium: a sequela of COVID-19 Prolonged and Late-Onset Symptoms of 296 Clinical features of patients infected with 2019 novel 397 coronavirus in Wuhan Interferon-gamma is a 399 potent inducer of catagen-like changes in cultured human anagen hair follicles Clinical criteria for COVID-19-associated 402 hyperinflammatory syndrome: a cohort study StatPearls. Treasure Island (FL) Being a Risk Factor of Alopecia Areata: Results of a National Cohort Study in South 406 Evaluation of the Relationship 408 between Alopecia Areata and Viral Antigen Exposure Alopecia areata: a review of disease 411 pathogenesis